NSE: SBILIFE | BSE: 540719

Strong Performer, Getting Expensive

Download real time

1830.20 16.00 (0.88%)

33.34% Gain from 52W Low

519.3K NSE+BSE Volume

NSE 12 Sep, 2025 3:31 PM (IST)

183,473

Market Cap

Market Runner Up

0.9

Beta 1Year

Low volatility

SBI Life Insurance Company Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SBILIFE, BSE:540719 SBI Life Insurance Company Ltd.

SBI Life Insurance Company Ltd.

25 Jul 2024

1830.20

0.88%

Target

ICICI Securities Limited

We remain constructive on SBI Life Insurance (SBLI) basis strength in its distribution and cost structure. While these business moats remain extremely relevant, the wide customer base also makes SBLI least vulnerable to regulatory changes.

SBI Life Insurance Company Ltd. has gained 29.89% in the last 6 Months

SBI Life Insurance Company Ltd.

24 Jul 2024

1830.20

0.88%

Growth and margin guidance reaffirmed; reiterate BUY

Buy: SBI Life Insurance Company...

Target

Emkay

SBI Life delivered a largely in-line performance during Q1FY25, with APE at Rs36.4bn (+20% YoY) vs. our estimate of Rs35.8bn and VNB margin at 26.8% (Emkay: 27.2%).

SBI Life Insurance C.. has an average target of 2084.20 from 10 brokers.

SBI Life Insurance Company Ltd.

24 Jul 2024

1830.20

0.88%

Gross premium in line; VNB margin contracts to 26.8%

Buy: SBI Life Insurance Company...

Target

Motilal Oswal

SBI Life Insurance (SBILIFE) reported a decent performance in 1QFY25. APE grew 20% YoY (in line) to INR36.4b, whereas absolute VNB grew 11.5% YoY.

SBI Life Insurance C.. has an average target of 2084.20 from 10 brokers.

SBI Life Insurance Company Ltd.

29 Apr 2024

1830.20

0.88%

SBI Life Insurance Company

Results Update: SBI Life Insurance Company...

SMC online

SBI Life Insurance Company Ltd. is trading below its 30 day SMA of 1831.3

SBI Life Insurance Company Ltd.

29 Apr 2024

1830.20

0.88%

Growth and margin have levers to maintain sectoral outperformance

Buy: SBI Life Insurance Company...

Target

ICICI Securities Limited

SBI Life Insurance (SBLI) maintains its sectoral outperformance in FY24 basis volume growth (17%), VNB growth (9%), core RoEV (21.8%) as well as overall RoEV (26%).

SBI Life Insurance Company Ltd. is trading above its 200 day SMA of 1634.3

SBI Life Insurance Company Ltd.

27 Apr 2024

1830.20

0.88%

Ends FY24 on high note; best placed amid volatile regulatory environment

Buy: SBI Life Insurance Company...

Target

Emkay

SBI Life logged a robust performance for FY24, with APE at Rs197bn meeting
our estimate. VNB margin at 28.1% was 0.6ppt ahead of our estimate leading
to VNB at Rs55.5bn beating our estimate by 3%.

SBI Life Insurance C.. has an average target of 2084.20 from 10 brokers.

SBI Life Insurance Company Ltd.

27 Apr 2024

1830.20

0.88%

SBI Life (BUY): Expect market dominance to continue

Buy: SBI Life Insurance Company...

Target

BOB Capital Markets Ltd.

FY24 APE growth strong at 17% YoY with ULIPs forming 60% of total; continues to lead the market with 23.3% share in individual APE

SBI Life Insurance C.. has an average target of 2084.20 from 10 brokers.

SBI Life Insurance Company Ltd.

26 Apr 2024

1830.20

0.88%

VNB in line; margin improves QoQ

Buy: SBI Life Insurance Company...

Target

Motilal Oswal

SBILIFE reported decent performance in 4QFY24. APE grew 17% YoY (in
line), while VNB rose 5% YoY as margins improved 90bp QoQ to 28.3%. PAT
grew 4.4% YoY to INR8.1b (12% beat vs. our estimate of INR7.2b).

SBI Life Insurance Company Ltd. is trading below its 30 day SMA of 1831.3

SBI Life Insurance Company Ltd.

29 Jan 2024

1830.20

0.88%

First Light | Bajaj Auto, TVS Motor, SBI Card, Laurus Labs, Cipla, Mahanagar Gas, DCB Bank, SBI Life

Buy: SBI Life Insurance Company...

BOB Capital Markets Ltd.

BJAUT: Healthy revival but priced in; downgrade to SELL. TVSL: On a fast track raise to BUY. SBICARD: Asset quality concerns persist; downgrade to HOLD. LAURUS: Challenges galore cut to SELL. CIPLA: Healthy revenue growth, strong margins. MAHGL: Volume growth accelerating, reiterate BUY. DCBB: NII sequentially flat on high interest cost. SBILIFE: ULIP-led growth; maintains market leadership